Skip to main content

Evidence gap analysis

Strategic analysis of the sufficiency of evidence to obtain reimbursement and HTA approval in Europe and recommendations about evidence generation

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Dutch Healthcare Authority published draft release of the DRG package for 2025

On December 21, 2023, the Dutch Healthcare Authority (NZa) published a concept release of the DRG package for 2025 (RZ25a). Eight new procedure codes, including, as an example, new codes for laparoscopic myoma enucleation and gene therapy.

Furthermore, four new diagnosis codes (for example, for several sub-types for chronic heart failure) were introduced.

In addition, five new supplementary payments (OZPs), and one new DRG, were introduced. Some of these concern the following procedures: treatment with tumor-infiltrating lymphocytes for skin cancer, intensive rehabilitation for teenagers/young adults with acquired brain damage.

The definitive release of the DRG package for 2025 (RZ25a) will be published by the NZa no later than May 1, 2024. 

See more information in Dutch here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.